Biocredit Antigen Test

VITROS SARS CoV2 Antigen CLIA based Examine

Description

Lateral motion immunochromatographic assay that adopted twin color system.
For the qualitative detection of SARS-CoV-2 antigen from nasopharyngeal swab specimen.
The verify incorporates colloid gold conjugate pad and a membrane strip pre-coated with antibodies specific to SARS-CoV-2 antigen on the verify traces (T).
A visible black band (antibody-antigen-antibody gold conjugate sophisticated) appears on the verify traces (T) If SARS-CoV-2 antigen is present throughout the specimen.
The administration line (C) reveals that verify is carried out appropriately.
Evaluated with panel specimen (n = 75) by PCR
Sensitivity: 90,2 %
Specificity: 100 %

Diagnostics

1. The VITROS SARS CoV2 Antigen assay is a chemiluminescent immunoassay meant for the qualitative
detection of SARS-CoV-2 nucleocapsid antigens in nasopharyngeal (NP) specimens from individuals who
are suspected of COVID-19 inside one to five days of the onset of indicators, or mid-turbinate specimens
collected from asymptomatic individuals.
2. The assay must be carried out in VITROS 3600 Immunodiagnostics system or VITROS 5600 / VITROS XT 7600
Constructed-in system from Ortho.

Features

COVID-19, Nasopharyngeal swabs

 

SKU:G61RHA20

AVAILABILITY:In Stock with The Lowest Value throughout the Market

SHIPMENT:Related Day Cargo Orders Sooner than 14

H00SIZE:20 Exams/KitSPECIFICITY:98.90%

Type

Immunochromatography speedy verify

Biocredit Rapigen One Step Rapid Test
Biocredit Rapigen One Step Rapid Test

Guidance for use of VITROS SARS CoV2 Antigen CLIA based Examine from Ortho Medical

Calibration Differ

Qualitative

VITROS SARS CoV2 antigen assay – Procedural Steps: –

Stage 1: Nasopharyngeal swab specimen assortment:
1. Purchase a nasopharyngeal swab specimen by inserting the sterile swab into the nostril.
2. Push the sterile swab until resistance is met on the stage of the turbinate.
3. Rotate the sterile swab plenty of events in direction of the nasopharyngeal wall & go away throughout the place for
10 seconds to saturate the swab tip.
4. Take away the swab from the nostril fastidiously.
5. Place the swab specimen into the viral transport medium buffer tube and shut the tube tightly.
6. Transport the swab sample in VTM to the laboratory in a cold chain.
7. The sample may very well be saved in Room temperature (Beneath 30◦C) for as a lot as 24 hrs from the time of
sample assortment or at 2 – 8◦C for as a lot as 48 hrs from the time of sample assortment.

Stage 2: Sample preparation for testing:

1. Sample preparation should be carried out in BSL-2 stage cabinet throughout the Laboratory.
2. Mix the swab specimen in VTM tube properly (vortex roughly 3-5 seconds).
3. Change 100 μL VITROS SARS-CoV-2 Antigen Extraction Buffer proper right into a labelled new sample tube.
4. Add 400 μL viral sample to the above tube (to deal with 1:4 ratio of extraction buffer: sample)
5. Mix properly (Cap/Plug the sample tube and vortex roughly 3-5 seconds).

Truenat™ COVID-19

601430020 20T
EUR 240

Truenat™ COVID-19

601430050 50T
EUR 600

COVID-19 Spike Antigen

30-2018 1 mg
EUR 400
Description: COVID-19 Spike recombinant antigen

COVID-19 Spike Antigen

30-2019 1 mg
EUR 400
Description: COVID-19 Spike recombinant antigen

COVID-19 Nucleocapsid protein

30-2005 1 mg
EUR 700
Description: COVID-19 Nucleocapsid protein recombinant antigen

COVID-19 Nucleocapsid protein

30-2006 1 mg
EUR 700
Description: COVID-19 Nucleocapsid protein recombinant Antigen

COVID-19 Nucleocapsid antigen

30-2020 1 mg
EUR 400
Description: COVID-19 Nucleocapsid recombinant protein

COVID-19 Nucleocapsid antigen

30-2021 1 mg
EUR 400
Description: COVID-19 Nucleocapsid recombinant protein

COVID-19 Nucleoprotein antibody

10-2890 1 mg
EUR 420
Description: Purified COVID-19 Nucleoprotein Antibody

COVID-19 Nucleoprotein antibody

10-2891 1 mg
EUR 420
Description: Purified COVID-19 Nucleoprotein Antibody

COVID-19 Nucleoprotein antibody

10-2894 1 mg
EUR 420
Description: Purified COVID-19 Nucleoprotein Antibody

STAT-NAT COVID-19 B

BSV-qPCR-12 24 tests Ask for price
Description: STAT-NAT COVID-19 B

STAT-NAT COVID-19 HK

BSV-qPCR-13 24 tests Ask for price
Description: STAT-NAT COVID-19 HK

COVID-19 IgG & IgM antibody

GEN-50001-50tests 50 tests
EUR 388.8
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus.

STAT-NAT COVID-19 MULTI

BSV-qPCR-11 96 tests Ask for price
Description: STAT-NAT COVID-19 MULTI

Coronavirus (COVID-19) CE IVD

PRD-Z-Path-COVID-19-CE 96 tests Ask for price
Description: Coronavirus (COVID-19) CE IVD

COVID-19 Antigen Rapid Test

ICOV-802H 25 Tests
EUR 12.5

COVID-19 Antigen Detection Kit

BSV-G61RHA20 20 tests Ask for price
Description: COVID-19 Antigen Detection Kit

BioSURE COVID-19 IgG Antibody Self-Test

BSV-C19 1 Test Ask for price
Description: BioSURE COVID-19 IgG Antibody Self-Test

COVID-19 nucleoprotein ELISA Kit

EKF60838-48T 48T
EUR 400.4

COVID-19 nucleoprotein ELISA Kit

EKF60838-5x96T 5x96T
EUR 2717

COVID-19 nucleoprotein ELISA Kit

EKF60838-96T 96T
EUR 572

COVID-19 Envelope Protein Antibody

E38PA9967 100ul
EUR 225
Description: Available in various conjugation types.

COVID-19 Spike glycoprotein Antibody

E38PA9966 100ul
EUR 225
Description: Available in various conjugation types.

COVID-19 Nucleocapsid Protein Antibody

E38PA9965 100ul
EUR 225
Description: Available in various conjugation types.

COVID-19 Nucleocapsid recombinant antigen

00221-V-100ugvial 100 ug/vial
EUR 150
Description: COVID-19 Nucleocapsid recombinant antigen

COVID-19 Nucleocapsid recombinant antigen

00221-V 1 MG
EUR 850

Nadal COVID-19 IgG/IgM Test

BSV-243001N-10 10 tests Ask for price
Description: Nadal COVID-19 IgG/IgM Test

GA COVID-19 Rapid Antigen Test

BSV-3980 20 tests Ask for price
Description: GA COVID-19 Rapid Antigen Test

SARS-CoV-2 (COVID-19) Spike Antibody (biotin)

3525-biotin-002mg 0.02 mg
EUR 229.7
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike Antibody (biotin)

3525-biotin-01mg 0.1 mg
EUR 594.26
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

Leave a Reply

Your email address will not be published. Required fields are marked *